Ceapro Inc. (CRPOF) Aktienanalyse
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ceapro Inc. (CRPOF) ist im Healthcare-Sektor taetig, zuletzt notiert bei $ mit einer Marktkapitalisierung von 0. Bewertet mit 46/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.
Zuletzt analysiert: 17. März 2026Ceapro Inc. (CRPOF) Gesundheitswesen & Pipeline-Uebersicht
Ceapro Inc. is a biotechnology company specializing in the development and commercialization of plant-derived active ingredients for the healthcare and cosmeceutical industries. With proprietary extraction technologies, Ceapro focuses on oat beta glucan and avenanthramides, targeting markets in the United States, Germany, China, and Canada.
Investmentthese
Ceapro Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its proprietary extraction technologies and focus on plant-derived active ingredients. The company's potential lies in the growing demand for natural and sustainable ingredients in the healthcare and cosmetic industries. However, with a negative P/E ratio of -3.74 and a negative profit margin of -48.9%, the company's financial performance raises concerns. Key growth catalysts include successful commercialization of its active ingredients and expansion into new markets. Investors should carefully consider the risks associated with the company's financial performance and competitive landscape. The company's beta of 1.38 suggests higher volatility compared to the market.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Market Cap of $0.01B indicates a small-cap company with potential for growth but also higher risk.
- P/E Ratio of -3.74 reflects negative earnings, suggesting the company is currently not profitable.
- Gross Margin of 37.0% indicates the percentage of revenue exceeding the cost of goods sold.
- Beta of 1.38 suggests the stock is more volatile than the market average.
- Profit Margin of -48.9% indicates significant losses relative to revenue.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary extraction technologies
- Focus on plant-derived active ingredients
- Presence in multiple geographic markets
- Two distinct business segments (Active Ingredient and Cosmeceutical)
Schwaechen
- Negative P/E ratio and profit margin
- Small market capitalization
- Reliance on online sales for cosmeceutical products
- Limited financial resources
Katalysatoren
- Upcoming: Potential regulatory approvals for new active ingredients.
- Ongoing: Expansion of online sales and marketing efforts.
- Ongoing: Development of new cosmeceutical products.
- Upcoming: Announcement of strategic partnerships with other companies.
Risiken
- Potential: Intense competition in the biotechnology industry.
- Potential: Regulatory scrutiny and compliance requirements.
- Ongoing: Fluctuations in raw material prices.
- Ongoing: Negative P/E ratio and profit margin.
- Potential: Economic downturns affecting consumer spending.
Wachstumschancen
- Expansion into New Markets: Ceapro Inc. has the opportunity to expand its geographic reach beyond its current markets in the United States, Germany, China, and Canada. Targeting new markets in Asia and Europe could drive revenue growth and increase market share. The global market for natural ingredients in cosmetics is projected to reach $36 billion by 2027, providing a significant opportunity for Ceapro to capitalize on its plant-derived active ingredients. This expansion could occur within the next 2-3 years.
- Development of New Products: Ceapro Inc. can invest in research and development to create new products based on its proprietary extraction technologies. Developing new active ingredients and formulations could attract new customers and increase revenue. The market for anti-aging products is expected to reach $83.2 billion by 2027, offering a significant opportunity for Ceapro to expand its cosmeceutical product line. This development could begin within the next year.
- Strategic Partnerships: Ceapro Inc. can form strategic partnerships with other companies in the healthcare and cosmetic industries to expand its distribution network and access new markets. Partnering with established players could accelerate growth and reduce risk. The global market for healthcare partnerships is estimated at $1.2 trillion, indicating substantial opportunities for collaboration. These partnerships could be established within the next 1-2 years.
- Increased Online Sales: Ceapro Inc. can focus on increasing its online sales through its website and other e-commerce platforms. Enhancing its online marketing efforts and improving the customer experience could drive revenue growth. The global e-commerce market is projected to reach $6.5 trillion in 2023, providing a significant opportunity for Ceapro to expand its online sales. This initiative can be implemented immediately.
- Licensing of Technology: Ceapro Inc. can license its proprietary extraction technologies to other companies in the healthcare and cosmetic industries. Licensing its technology could generate revenue and expand its market reach without requiring significant investment. The global market for technology licensing is estimated at $400 billion, indicating substantial opportunities for Ceapro to monetize its intellectual property. Licensing agreements could be pursued within the next year.
Chancen
- Expansion into new geographic markets
- Development of new products and formulations
- Strategic partnerships with other companies
- Increased online sales and marketing efforts
Risiken
- Intense competition in the biotechnology industry
- Regulatory scrutiny and compliance requirements
- Fluctuations in raw material prices
- Economic downturns affecting consumer spending
Wettbewerbsvorteile
- Proprietary extraction technologies provide a competitive advantage.
- Focus on plant-derived active ingredients aligns with consumer demand for natural products.
- Established presence in the healthcare and cosmetic industries.
Ueber CRPOF
Ceapro Inc., established in 1997 and headquartered in Edmonton, Canada, is a biotechnology company dedicated to the development and marketing of health and wellness products and technologies based on plant extracts. The company operates through two primary segments: Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment focuses on developing proprietary extraction technologies and applying these technologies to the production, development, and commercialization of active ingredients. Key products include oat beta glucan and avenanthramides, derived from oats and other renewable plant resources, which are utilized in the healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients. These products are sold directly to end-users primarily through online website sales and through select natural products stores. Ceapro's geographic reach extends to the United States, Germany, China, Canada, and other international markets. The company aims to leverage its proprietary technologies to create value-added products in the health and wellness space.
Was das Unternehmen tut
- Develop and market health and wellness products.
- Specialize in plant extract-based products.
- Operate in the Active Ingredient Product Technology Industry.
- Operate in the Cosmeceutical Industry.
- Develop proprietary extraction technologies.
- Commercialize active ingredients like oat beta glucan and avenanthramides.
- Produce anti-aging products derived from natural active ingredients.
Geschaeftsmodell
- Develop and sell active ingredients to healthcare and cosmetic companies.
- Develop and sell cosmeceutical products directly to consumers through online sales.
- Generate revenue through the sale of plant-derived active ingredients and cosmeceutical products.
Branchenkontext
Ceapro Inc. operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for natural and sustainable ingredients in healthcare and cosmetics is growing, driven by consumer demand for cleaner and more environmentally friendly products. Ceapro competes with other biotechnology companies, including ABDXF, AMHV, EIGRQ, LVCLY, and NOXOF, that are also developing and marketing plant-derived active ingredients. The industry is subject to regulatory scrutiny and requires significant investment in research and development.
Wichtige Kunden
- Healthcare companies that use active ingredients in their products.
- Cosmetic companies that use active ingredients in their products.
- End-users who purchase cosmeceutical products directly through online sales.
Finanzdaten
Chart & Info
Ceapro Inc. (CRPOF) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Monday
· 2. Dez. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer CRPOF.
Kursziele
Wall-Street-Kurszielanalyse fuer CRPOF.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von CRPOF auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Fuehrung: Gilles R. Gagnon
CEO
Gilles R. Gagnon serves as the CEO of Ceapro Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions in companies focused on drug development and commercialization. Gagnon's expertise spans strategic planning, business development, and financial management. He is known for his ability to drive growth and innovation in the healthcare sector. His educational background includes advanced degrees in business and science.
Erfolgsbilanz: Under Gilles R. Gagnon's leadership, Ceapro Inc. has focused on expanding its product portfolio and strengthening its market position. Key achievements include the development and commercialization of new active ingredients and cosmeceutical products. He has also overseen the expansion of the company's geographic reach and the establishment of strategic partnerships. His tenure has been marked by a commitment to innovation and sustainable growth.
CRPOF OTC-Marktinformationen
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ceapro Inc. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. This tier is also known as the Pink Open Market.
- OTC-Stufe: OTC Other
- Offenlegungsstatus: Unknown
- Limited regulatory oversight on the OTC Other tier increases the risk of fraud and manipulation.
- Lack of financial transparency due to limited disclosure requirements.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for delisting or trading suspension.
- Increased difficulty in obtaining accurate and reliable information about the company.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review audited financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the company's capital structure and potential dilution.
- Review any legal or regulatory issues facing the company.
- Consult with a qualified financial advisor.
- The company has been in operation since 1997.
- Ceapro Inc. has a portfolio of proprietary extraction technologies.
- The company has a presence in multiple geographic markets.
- Ceapro Inc. has a CEO with experience in the biotechnology industry.
CRPOF Healthcare Aktien-FAQ
What are the key factors to evaluate for CRPOF?
Ceapro Inc. (CRPOF) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary extraction technologies. Primary risk to monitor: Potential: Intense competition in the biotechnology industry.. This is not financial advice.
How frequently does CRPOF data refresh on this page?
CRPOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRPOF's recent stock price performance?
Recent price movement in Ceapro Inc. (CRPOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary extraction technologies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRPOF overvalued or undervalued right now?
Determining whether Ceapro Inc. (CRPOF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRPOF?
Before investing in Ceapro Inc. (CRPOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding CRPOF to a portfolio?
Potential reasons to consider Ceapro Inc. (CRPOF) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary extraction technologies. Additionally: Focus on plant-derived active ingredients. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of CRPOF?
Yes, most major brokerages offer fractional shares of Ceapro Inc. (CRPOF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track CRPOF's earnings and financial reports?
Ceapro Inc. (CRPOF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for CRPOF earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.